#USA #Hong Kong #ASC30 #Ascletis Pharma #ASC39

Ascletis Makes Strides in Obesity Treatment with ASC30_39 FDC

In a significant advancement for obesity management, Ascletis Pharma Inc. recently announced the selection of ASC30_39 FDC, a novel fixed-dose combination of ASC30 and ASC39, marking it as a promising candidate for clinical development. This innovative therapy combines two once-daily oral small molecules designed to enhance patient compliance and treatment efficacy for obesity.

The Science Behind the Combination

The ASC30_39 FDC contains ASC30, a GLP-1 receptor agonist, and ASC39, an amylin-selective agonist. In recent studies, the combination showed superior pharmacokinetic profiles comparable to those of their individual formulations. Specifically, dogs administered the ASC30_39 FDC demonstrated excellent oral bioavailability, showcasing high drug exposure and significant effectiveness over a prolonged half-life of up to 12 hours. Such attributes are critical for a therapy designed to be taken once daily.

The compatibility of ASC30 and ASC39 within the fixed-dose tablet is noteworthy. Developed using Ascletis' proprietary formulation techniques, these tablets maintain room temperature stability and present a compact pill size. The result is a user-friendly treatment modality that addresses a prevalent health issue while enhancing medication adherence.

Clinical Readiness and Regulatory Pathway

Currently, ASC30 is prepared to enter Phase III clinical trials and boasts a favorable gastrointestinal (GI) profile, exhibiting half the vomiting rate in comparison to orforglipron during titration phases. Meanwhile, ASC39 has showcased notable efficacy in preclinical models, providing evidence of its potential as an effective amylin analog. With Ascletis poised to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), the anticipation surrounding this combined therapy is palpable, expected to take place in the third quarter of 2026.

Vision for Future Patient Outcomes

"The selection of this fixed-dose combination represents a pivotal step towards developing a novel oral therapy that merges the strengths of both ASC30 and ASC39," stated Dr. Jinzi Jason Wu, Founder and CEO of Ascletis. Emphasizing the unique advantage of this fusion, he mentioned, “We see the potential not only to enhance patient outcomes but to change the landscape of obesity treatment with improved drug exposure and a minimized side effect profile.”

As Ascletis continues its mission to innovate within the medical realms of metabolic diseases, the combination of ASC30 and ASC39 could redefine approaches towards chronic weight management. This could provide a much-needed breakthrough in combating obesity, showcasing Ascletis’ commitment to develop next-generation therapeutics focused on improving quality of life and healthcare delivery. With the clinical trial roadmap taking shape, expectations are high that these efforts will culminate in successful advancements for patients grappling with obesity.

About Ascletis Pharma Inc.

Ascletis Pharma operates as a fully integrated biotechnology firm dedicated to pioneering therapeutics for metabolic diseases. Its innovative technologies, including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and various peptide enhancement techniques, underline its commitment to creating best-in-class medications. The company is publicly traded on the Hong Kong Stock Exchange under the ticker 1672.HK.

For additional insights, visit www.ascletis.com.